Interventions for the Prevention of Preterm Premature Rupture of Membranes: A Systematic Review and Meta-Analysis.


Journal

Fetal diagnosis and therapy
ISSN: 1421-9964
Titre abrégé: Fetal Diagn Ther
Pays: Switzerland
ID NLM: 9107463

Informations de publication

Date de publication:
2022
Historique:
received: 11 05 2022
accepted: 27 05 2022
pubmed: 1 7 2022
medline: 20 8 2022
entrez: 30 6 2022
Statut: ppublish

Résumé

Preterm prelabour rupture of membranes (PPRoM) is a significant cause of maternal and perinatal morbidity and mortality. The aim of this project was to identify interventions that reduce the prevalence of PPRoM. Search strategy included a systematic literature search of MEDLINE, EMBASE, PubMed, and Cochrane Library. The selection criteria included randomized control studies that compared a therapy to standard care (no therapy or placebo) in pregnancy and included PPRoM as an outcome. Risk of bias was assessed according to the Cochrane risk-of-bias tool for randomized trials. Odds ratios with 95% confidence intervals were calculated using random-effects models. Quality of evidence was assessed using the GRADE methodology. Twenty-nine studies examining 10 interventions met the inclusion criteria. Therapies included docosahexaenoic acid (DHA), aspirin, rofecoxib, vitamin C alone and with vitamin E, folic acid (alone, with iron, with iron and zinc, within a multiple micronutrient supplement), zinc, calcium, copper, and treatment of bacterial vaginosis. There was no significant difference in the prevalence of PPRoM in the treatment groups compared to placebo, except for rofecoxib which showed an increased risk of PPRoM (RR 2.46, 95% CI 1.28-4.73; p = 0.007, 1 trial, 98 women; very low quality of evidence) and a multiple micronutrient supplement which showed a reduction in PPRoM (RR 0.40, 95% CI 0.19-0.84; p = 0.01, 1 trial, 1,671 women; very low quality of evidence). No interventions have been convincingly shown to reduce the prevalence of PPRoM. Given this is a common problem leading to significant morbidity and mortality, further research is required.

Identifiants

pubmed: 35772387
pii: 000525655
doi: 10.1159/000525655
doi:

Substances chimiques

Micronutrients 0
Iron E1UOL152H7
Zinc J41CSQ7QDS

Types de publication

Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-278

Informations de copyright

© 2022 S. Karger AG, Basel.

Auteurs

Vanessa El-Achi (V)

Department of Maternal and Fetal Medicine, Liverpool Hospital, Sydney, New South Wales, Australia.

Sangita Aggarwal (S)

Women and Babies Department, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Jon Hyett (J)

Discipline of Obstetrics and Gynaecology, Western Sydney University, Sydney, New South Wales, Australia.
Academic Obstetric Group, Ingham Institute for Applied Medical Research, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH